Marks Group Wealth Management Inc Boosts Stock Holdings in Astrazeneca Plc $AZN

Marks Group Wealth Management Inc lifted its stake in shares of Astrazeneca Plc (NYSE:AZN) by 9.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,787 shares of the company’s stock after acquiring an additional 3,337 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Astrazeneca were worth $6,632,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of AZN. Triumph Capital Management purchased a new stake in shares of Astrazeneca during the third quarter worth $25,000. Bangor Savings Bank grew its stake in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new position in shares of Astrazeneca during the fourth quarter worth $30,000. YANKCOM Partnership acquired a new position in shares of Astrazeneca during the fourth quarter worth $31,000. Finally, TFC Financial Management Inc. grew its stake in shares of Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

NYSE AZN opened at $181.81 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a market capitalization of $281.97 billion, a PE ratio of 27.30, a P/E/G ratio of 1.59 and a beta of 0.25. The company has a fifty day moving average of $190.70 and a two-hundred day moving average of $185.53.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, analysts expect that Astrazeneca Plc will post 9.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Thursday, May 21st. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.